Bionomics' extra overseas expenses eligible for R&D Tax Incentive
08 October, 2013Bionomics (ASX:BNO) has received additional decisions from Innovation Australia in relation to the company's applications for an advance finding under the R&D Tax Incentive.
Clinical Genomics acquires cancer-screening lab Enterix
08 October, 2013Clinical Genomics recently acquired the US-based cancer screening company Enterix.
The 2013 Nobel Prize in Physiology or Medicine
08 October, 2013Three scientists' work on a major transport system in cells has won them the 2013 Nobel Prize in Physiology or Medicine.
Mental Health Research Alliance
04 October, 2013Queensland's key health research institutes have joined forces to create the Queensland Mental Health Research Alliance.
GTG completes $3m share purchase plan
04 October, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has completed the SPP stage of its capital raising and revealed that underwriter Cygnetl has committed to buy an extra $1m worth of shares.
Prima re-evaluating CVac trial design
04 October, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) is re-evaluating using PFS as a primary objective of an upcoming trial of its CVac cancer immunotherapy candidate, based on results to date of an earlier study.
Former Alchemia CEO joins Ascend as chairman
03 October, 2013 by Dylan Bushell-EmblingDr Peter Smith, former CEO of Alchemia (ASX:ACL), has joined Ascend Biopharmaceuticals as its board chairman.
Research Alliance calls for strategic research policy
02 October, 2013Research Alliance advocates for science, research and innovation to have steady and purposeful support.
Vic biotechs win out in Technology Voucher program
27 September, 2013 by Dylan Bushell-EmblingThe Victorian Government has awarded Technology Development vouchers worth up to $50K for 10 high-tech projects, including research into potential treatments for Crohn's disease.
Linking immunity and cancer progression
27 September, 2013An explanation for how a subset of ovarian cancers block the body's early anti-tumour immune response may expand treatment options for patients.
New cancer drugs threaten to stretch PBS thin
24 September, 2013 by Dylan Bushell-EmblingAdvancements in fighting cancer are also driving up the cost of cancer drugs, which could present a major strain on PBS resources, according to Flinders University’s Michael Sorich.
Bioniche to raise $10m through equity offer
20 September, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has launched a $10m capital raising in Canada to ensure it has funds to continue development of cancer treatment Urocidin while it sells its animal health unit.
Creative prize for early-career researchers
19 September, 2013Applications are open for The Centenary Institute Lawrence Creative Prize for early-career biomedical researchers.
Viralytics meets primary goal of melanoma trial
19 September, 2013 by Dylan Bushell-EmblingA phase II trial of Viralytics' (ASX:VLA) Cavatak cancer-targeting virus in late-stage melanoma is still recruiting patients but has already met its primary endpoint.
New government, no science portfolio
17 September, 2013The incoming ministry for the newly elected Australian Government has been unveiled.
